CureBiotech

CureBiotech is a South Korean biotechnology company specializing in the development of next-generation cell therapies for solid tumors. The company utilizes its proprietary Cure-Platform to engineer enhanced CAR-T and CAR-NK cells designed to overcome the immunosuppressive microenvironment of solid cancers. Its lead candidate, CB-101, is a mesothelin-targeted CAR-T therapy currently in Phase 1 clinical development for various solid malignancies. CureBiotech also maintains a pipeline of CAR-NK programs targeting antigens such as Claudin 18.2 and Glypican-3. The company aims to provide curative options for patients with refractory solid tumors through innovative immune cell engineering and optimized manufacturing processes.